Data Analysis

New OHE research puts the economic burden of obesity in eight European countries at 0.7% to 1.4% of GDP. Germany carries the largest bill at EUR 55.2bn; the UK carries the largest productivity share at 58%. #SyenzaAI #SyenzaNews #MarketAccess #HealthEconomics #Obesity

Sweden's pharmaceutical injury insurance logged 33 semaglutide adverse reactions claims in the first eight months of 2026, up from 13 in all of 2025. More prescribing and more awareness explain the rise better than any new risk. #SyenzaNews #pharmaceuticals #drugsafety #regulatoryaffairs

From 12 September 2026, new connected medical devices on the EU market must be designed for default data access, handing hospitals control of the data their equipment generates. #SyenzaNews #DataAct #MedicalDevices #MarketAccess

A real-world study from Eli Lilly finds sustained Zepbound use lowers healthcare costs in adults over 55, with savings exceeding the Medicare GLP-1 Bridge price within 12 months. #SyenzaNews #MarketAccess #Obesity #HealthEconomics

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have opened a public consultation on a draft EMRN data standards framework, the governance document that will shape how the European medicines regulatory network adopts, creates, updates, and implements data standards for human and veterinary medicines. The draft, published under reference EMA/185661/2026 and dated 1 July 2026, is open for comment from 17 August to 18 September 2026. Responses go through an EUSurvey form linked in the consultation […]

EMA and HMA have opened a public consultation on the draft EMRN Data Standards Framework, which sets out how the EU will govern data standards for medicines regulation. Comments close 18 September 2026.

The NICE Decision Support Unit and EEPRU have released updated Stata, Excel and R commands for mapping EQ-5D-3L data to the new EQ-5D-5L value set, giving UK HTA analysts a validated route to convert legacy three-level utility data ahead of NICE's adoption of the five-level value set.

How can real-world data networks improve safety evaluations for multiple sclerosis therapies? A new collaborative MS data initiative is enabling more robust assessments of treatment safety by pooling patient insights across sources. Discover how this approach is advancing evidence generation in neurology. #SyenzaNews #digitalhealth #clinicaltrials #datascience #innovation

Is the Dutch health insurance fund heading back into the red? Projections show the Zorgverzekeringsfonds returning to an operating deficit in 2026, raising fresh questions about long-term sustainability and the balance between premiums, benefits, and public spending. Read the full analysis to see what this means for healthcare financing. #SyenzaNews #healthcare #HealthEconomics #MarketAccess #healthcarepolicy

🚀 What sparked China's pharmaceutical innovation surge after 2016? Key regulatory reforms streamlined approvals and accelerated R&D, rapidly elevating the country’s role in global drug development. Explore the data and trends behind this transformation. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

How can Health Technology Assessment reshape funding for social care? Our latest analysis explores strategic approaches to HTA-informed funding and the vital role of support networks in building sustainable, equitable social care systems. Read the full piece to see how these strategies are driving meaningful change. #SyenzaNews #HealthEconomics #HealthcareInnovation #costeffectiveness #innovation

🔍 How did the pandemic expose critical weaknesses in Brazil’s pharmaceutical supply chain? From raw-material dependencies to distribution bottlenecks, COVID-19 disruptions laid bare vulnerabilities that continue to threaten medicine availability and market access across the region. Read the full analysis to see what these lessons mean for building more resilient supply systems. #SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #healthcarepolicy